The FY19 Defense Appropriation provides $130 million (M) to the United States Department of Defense Breast Cancer Research Program (BCRP) to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for servicemembers, veterans, and the general public. The sponsor deadline is Tuesday, March 12.
Applications submitted to the FY19 BCRP must address one or more of the following overarching challenges:
- Prevent breast cancer (primary prevention)
- Identify determinants of breast cancer initiation, risk, or susceptibility
- Distinguish deadly from non-deadly breast cancers
- Conquer the problems of overdiagnosis and overtreatment
- Identify what drives breast cancer growth; determine how to stop it
- Identify why some breast cancers become metastatic
- Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
- Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
- Eliminate the mortality associated with metastatic breast cancer
For additional information see: https://cdmrp.army.mil/funding/bcrp
If you are interesting in applying for this funding opportunity, please contact OSRP. Proposals must be completed and submitted to OSRP at least two business days prior to the deadline set by the sponsor.